biology-technology-1/senomyx-announces-corporate-update-and-third-quarter-2009-financial-results-14735-12/;/a> 

Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2 Dendreon Announces Pricing of Common Stock Offering 3 Successful Stem Cell Therapy for Treatment of Eye Disease 2 Successful Stem Cell Therapy for Treatment of Eye Disease 3 Successful Stem Cell Therapy for Treatment of Eye Disease 4 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3

[0] Dendreon Announces Pricing of Common Stock Offering [0] Successful Stem Cell Therapy for Treatment of Eye Disease [0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head [0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors

Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2 Hand Surgeons Take Ethics into Their Own Hands 3 Hand Surgeons Take Ethics into Their Own Hands 4 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4 National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1 National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2 National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7 Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8 Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1 Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2

[0] Hand Surgeons Take Ethics into Their Own Hands [0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug [0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology

biology-technology-1/senomyx-announces-corporate-update-and-third-quarter-2009-financial-results-14735-12/;/a>&nbsp;

biology-technology-1/senomyx-announces-corporate-update-and-third-quarter-2009-financial-results-14735-12/;/a>